COMy 2023 | The need to improve treatment options for patients with lenalidomide-refractory multiple myeloma
Hermann Einsele
• 12 May 2023
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, comments on the importance of identifying alternative therapies for patients with lenalidomide-refractory multiple myeloma. Prof. Einsele notes that a majority of patients receiving lenalidomide relapse during or shortly after therapy, highlighting the need for earlier treatment with novel agents such as bispecific antibodies (BsAbs) and CAR T-cells. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
